Article
GALNT2 sustains glioma stem cells by promoting CD44 expression
25 Mar 2023
Abstract excerpt
Glioblastoma (GBM) is the most prevalent and malignant brain tumor and is highly resistant to currently available treatment. In this study, we reveal that polypeptide N-acetylgalactosaminyltransferase 5 (GALNT2) expression level was elevated in GBM, IDH1 wildtype glioma, and GBM stem cells (GSCs). GALNT2 increased expression correlated with GBM patients’ unfavorable clinical outcomes. Functionally, targeting...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
